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In the HOPE (Heart Outcomes Prevention Evaluation)
trial, the angiotensin-converting enzyme (ACE) inhibitor
ramipril reduced the incidence of major cardiovascular
events, including cardiovascular death, stroke, and myocar-
dial infarction, in patients who had clinical evidence of
vascular disease or diabetes mellitus plus 1 additional car-
diovascular risk factor but presented without heart failure or
low left ventricular ejection fraction (1). In a population at
lower cardiovascular risk than that enrolled in the HOPE
trial and similarly presenting without apparent heart failure,
the EUROPA (European Trial on Reduction of Cardiac
Events with Perindopril in Stable Coronary Artery Disease)
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investigators found that perindopril was likewise effective in
reducing the rates of cardiovascular death and myocardial
infarction (2). Overall, these studies have provided a solid
basis for secondary prevention guidelines to assert that all
patients with coronary and other atherosclerotic vascular
disease manifestations, regardless of left ventricular function
and in the absence of contraindications, should be treated
with ACE inhibitors in addition to aspirin, beta-blockers,
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the HOPE and EUROPA populations did not include
patients with hypertension unless blood pressure was already
sufficiently controlled with other treatments, ACE inhibi-
tors are likely to exert direct actions beyond their hemody-
namic effects. The results of these 2 trials have therefore
stimulated research toward understanding how modulating
the renin-angiotensin system protects blood vessels and
possibly contributes to atherothrombotic risk reduction.
In this issue of the Journal, Willoughby et al. (4) add
another piece to the puzzle that elucidates putative effects of
ramipril beyond previously documented beneficial changes
to vasomotor function. The investigators addressed the
question of whether inhibiting the ACE with ramipril
results in more potent platelet responsiveness to the disag-
gregating effects of nitric oxide (NO) and thus beneficially
affect the so-called NO resistance phenomenon. NO is
formed from L-arginine by a 2-step oxidation to L-citrulline
catalyzed by the enzyme NO synthase (NOS). One of the 3
isoforms of NOS identified to date (NOS3) is expressed
constitutively in endothelial cells, which represent the main
source of vascular NO under physiological conditions.
Newly synthetized NO prompts a vasodilator effect by
diffusing from the endothelial cells to the subjacent vascular
smooth muscle cells, where it activates in a paracrine
manner the production of the second messenger cyclic
guanosine monophosphate (cGMP) by soluble heme-
containing enzyme guanylyl cyclase. Other cells expressing
NOS3 in the cardiovascular system include cardiac myo-
cytes, red blood cells, megakaryocytes, and platelets. Plate-
lets produce smaller amounts of NO than endothelial cells,
and NO generated from platelets exerts its effects in an
autocrine manner (Fig. 1). Stimulation of platelets by
aggregating agents activates platelet NOS3 and generates
NO as a negative feedback mechanism regulating platelet
recruitment, adhesion, and activation. NO generation is
impaired in cardiovascular disease and in the presence of
coronary risk factors and therefore might contribute to the
occurrence of thrombotic complications in combination
with the well-documented decrease in endothelium-derived
NO in these conditions (5).
In the study by Willoughby et al. (4), HOPE-like
patients (n  119) were randomized in a double-blind
fashion to receive ramipril (n  60) or placebo (n  59). At
12 weeks, there were no significant changes in the extent of
adenosine diphosphate–induced aggregation or in platelet
responsiveness to the antiaggregatory effects of NO-donor
sodium nitroprussiate in both groups. However, when
analyzing changes in sodium nitroprussiate response relative
to those in adenosine diphosphate response to address their
physiological antagonism, an increase in NO responsiveness
was found in the ramipril group (p  0.001), with onset of
the effect within 4 weeks. Intriguingly, the increase in
responsiveness with ramipril was confined mostly to patients
with baseline severe NO resistance (p  0.03), while no
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baseline platelet response. Ramipril marginally reduced
blood pressure but positively affected surrogate clinical markers
or arterial stiffness and endothelial dysfunction. In a further
echanistic study of a less NO responsive cohort (n  19),
ramipril was found to ameliorate NO resistance as early as at 2
weeks, with parallel increases in cGMP generation in response
to sodium nitroprussiate and no changes in plasma levels of
thrombospondin-1, a modulator of soluble guanylyl cyclase
activity, thereby implying that ramipril reduces NO resistance
by facilitation of thrombospondin-1–independent cGMP
generation.
The investigators should be commended for an elegantly
performed study, which indeed provides potential mecha-
nistic explanations for the reduction in cardiovascular isch-
emic events observed with ACE inhibitors in the HOPE
and EUROPA trials. However, a number of unsolved
questions remain. First, platelet NO responsiveness is a
relatively narrow characteristic of platelet physiology, and
the contribution of differences in platelet NO responsive-
ness to atherothrombotic risk in vivo remains unclear. By
promoting the activation of the cGMP-dependent protein
kinase, NO causes inhibition of platelet activation through
several pathways, including synergistic mechanisms to re-
duce cytosolic Ca2 levels and indirect inhibition of throm-
boxane A2 and glycoprotein IIb/IIIa receptors. However,
O can regulate platelet function independently of cGMP,
Figure 1 Platelet Pathways Leading to NO Production and Func
In platelets, nitric oxide (NO) is formed from L-arginine to L-citrulline by 1 of the 3 i
various stimuli activating NOS3 in platelets is provided. Platelet-derived NO inhibit
adenylyl cyclase; ADP  adenosine diphosphate; Akt  protein kinase B; AMPK 
2AR  beta-2-adrenoceptors; cAMP  cyclic adenosine monophosphate; GP  guch as by inhibiting exocytosis of platelet granules andecruitment of platelets to the growing thrombus. Further
tudies are clearly needed to clarify the magnitude and
ontribution of both cGMP-dependent and cGMP-
ndependent pathways through which NO may exert its
ffects on platelets. Second, the pathophysiological basis
i.e., reduction in guanylate cyclase sensitivity to NO and/or
cavenging of the released NO by O2-), as well as the
predictive factors and clinical implications of changes in NO
responsiveness, are uncertain. Therefore, linking findings
from mechanistic studies to large trials with cardiovascular
endpoints may sound speculative, when evidence of a direct
relationship with clinical outcomes is lacking. Indeed, the
possible association between ACE inhibitors and platelet
function may have been strengthened by investigating other
aspects of platelet physiology that have been more clearly
correlated with clinical cardiovascular outcomes, such as
light transmittance aggregometry (rather than whole-blood
impedance aggregometry) in response to adenosine diphos-
phate and other agonists, and flow cytometry–determined
markers of platelet activation (i.e., P-selectin, fibrinogen). It
should be noted that the reported effects of ACE inhibitors
on platelets as well as thrombotic markers have been quite
marginal to date. Finally, with only 19 “extreme” patients
with impaired platelet NO responsiveness and no placebo
comparator arm, the mechanistic substudy remains at best
hypothesis generating, and the contribution of the platelet
cGMP pathway in the ACE inhibitor effect should be
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